KR101868084B1 - 대환식 화합물 및 그의 제조방법 - Google Patents

대환식 화합물 및 그의 제조방법 Download PDF

Info

Publication number
KR101868084B1
KR101868084B1 KR1020137027773A KR20137027773A KR101868084B1 KR 101868084 B1 KR101868084 B1 KR 101868084B1 KR 1020137027773 A KR1020137027773 A KR 1020137027773A KR 20137027773 A KR20137027773 A KR 20137027773A KR 101868084 B1 KR101868084 B1 KR 101868084B1
Authority
KR
South Korea
Prior art keywords
compound
hcv
rti
formula
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137027773A
Other languages
English (en)
Korean (ko)
Other versions
KR20140057481A (ko
Inventor
스티븐 제임스 모스
매튜 앨런 그레고리
배리 윌킨슨
Original Assignee
뉴로바이브 파마슈티컬 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by 뉴로바이브 파마슈티컬 에이비 filed Critical 뉴로바이브 파마슈티컬 에이비
Publication of KR20140057481A publication Critical patent/KR20140057481A/ko
Application granted granted Critical
Publication of KR101868084B1 publication Critical patent/KR101868084B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
KR1020137027773A 2011-03-29 2012-03-29 대환식 화합물 및 그의 제조방법 Expired - Fee Related KR101868084B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GB1105293.3 2011-03-29
GB1113629.8 2011-08-08
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production
GB1202060.8 2012-02-07
PCT/GB2012/050700 WO2012131371A1 (en) 2011-03-29 2012-03-29 Macrocyclic compound and methods for its production

Publications (2)

Publication Number Publication Date
KR20140057481A KR20140057481A (ko) 2014-05-13
KR101868084B1 true KR101868084B1 (ko) 2018-06-18

Family

ID=46001313

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137027773A Expired - Fee Related KR101868084B1 (ko) 2011-03-29 2012-03-29 대환식 화합물 및 그의 제조방법
KR1020137028095A Expired - Fee Related KR101911484B1 (ko) 2011-03-29 2012-03-29 대환식 화합물 및 그의 제조방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137028095A Expired - Fee Related KR101911484B1 (ko) 2011-03-29 2012-03-29 대환식 화합물 및 그의 제조방법

Country Status (29)

Country Link
US (2) US9090657B2 (enExample)
EP (2) EP2691412B1 (enExample)
JP (2) JP6118792B2 (enExample)
KR (2) KR101868084B1 (enExample)
CN (3) CN103619869B (enExample)
AR (1) AR085724A1 (enExample)
AU (2) AU2012235880B2 (enExample)
BR (2) BR112013024974A2 (enExample)
CA (2) CA2830831C (enExample)
CL (2) CL2013002739A1 (enExample)
CY (2) CY1116318T1 (enExample)
DK (2) DK2691413T3 (enExample)
EA (2) EA023848B1 (enExample)
ES (2) ES2533438T3 (enExample)
HR (2) HRP20150187T1 (enExample)
IL (2) IL228509B (enExample)
JO (1) JO3063B1 (enExample)
MX (2) MX345351B (enExample)
MY (2) MY170637A (enExample)
PH (2) PH12013502000B1 (enExample)
PL (2) PL2691412T3 (enExample)
PT (2) PT2691412E (enExample)
RS (2) RS53963B1 (enExample)
SG (2) SG193568A1 (enExample)
SI (2) SI2691413T1 (enExample)
TW (1) TWI525098B (enExample)
UY (1) UY33993A (enExample)
WO (2) WO2012131371A1 (enExample)
ZA (2) ZA201307149B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019866A8 (pt) 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) * 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
JP2019535726A (ja) * 2016-11-18 2019-12-12 ネウロビベ プハルマセウトイカル エービー サングリフェリンマクロ環状類似体の抗がん化合物としての使用
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
WO2006138507A1 (en) 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
BRPI0806265A2 (pt) 2007-01-04 2011-09-06 Debiopharm Sa ciclosporina não-imunossupressora para tratamento de distrofia muscular congênita de ullrich
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
US8962329B2 (en) 2008-09-24 2015-02-24 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Gene cluster
BR112012019866A8 (pt) * 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
CN107090476B (zh) * 2010-12-20 2021-09-24 爱博利瓦有限公司 Sanglifehrin衍生物及其制备方法
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Org. Chem. 1999, 64, 9632-9639. 1부. *
Journal of Organic Chemistry, 1999, 64, p9632- *

Also Published As

Publication number Publication date
CN103619869B (zh) 2015-11-25
ES2533438T3 (es) 2015-04-10
EA023848B1 (ru) 2016-07-29
KR20140071958A (ko) 2014-06-12
SG193569A1 (en) 2013-11-29
IL228509A0 (en) 2013-12-31
DK2691412T3 (en) 2015-04-07
ES2533437T3 (es) 2015-04-10
ZA201307149B (en) 2015-04-29
IL228509B (en) 2018-02-28
JP6118793B2 (ja) 2017-04-26
CA2830827C (en) 2020-03-10
WO2012131371A1 (en) 2012-10-04
EA201391396A1 (ru) 2014-02-28
BR112013024965A2 (pt) 2017-04-18
MX345352B (es) 2017-01-26
PT2691412E (pt) 2015-03-25
SI2691413T1 (sl) 2015-05-29
EA201391399A1 (ru) 2014-02-28
KR101911484B1 (ko) 2018-10-24
US9139613B2 (en) 2015-09-22
SI2691412T1 (sl) 2015-05-29
JO3063B1 (ar) 2017-03-15
CN103619869A (zh) 2014-03-05
JP6118792B2 (ja) 2017-04-26
AR085724A1 (es) 2013-10-23
DK2691413T3 (en) 2015-04-07
CN103635484A (zh) 2014-03-12
TW201300398A (zh) 2013-01-01
EP2691413A1 (en) 2014-02-05
AU2012235961A1 (en) 2013-10-10
RS53964B1 (sr) 2015-08-31
EP2691413B1 (en) 2014-12-24
CL2013002739A1 (es) 2014-07-11
CN103635484B (zh) 2017-05-10
KR20140057481A (ko) 2014-05-13
MX2013011051A (es) 2014-03-13
AU2012235880B2 (en) 2016-11-17
HRP20150187T1 (xx) 2015-06-05
AU2012235880A1 (en) 2013-10-17
RS53963B1 (sr) 2015-08-31
ZA201307231B (en) 2015-05-27
US20120251581A1 (en) 2012-10-04
MX2013011043A (es) 2014-04-25
PH12013502000B1 (en) 2018-08-10
MX345351B (es) 2017-01-26
CY1116186T1 (el) 2017-02-08
MY170618A (en) 2019-08-21
PL2691413T3 (pl) 2015-05-29
PL2691412T3 (pl) 2015-08-31
AU2012235961B2 (en) 2016-09-01
JP2014514290A (ja) 2014-06-19
CA2830827A1 (en) 2012-10-04
CL2013002740A1 (es) 2014-07-11
EA023907B1 (ru) 2016-07-29
PH12013502016A1 (en) 2013-12-16
CA2830831C (en) 2020-03-10
EP2691412B1 (en) 2014-12-24
HK1189237A1 (en) 2014-05-30
CY1116318T1 (el) 2017-02-08
JP2014510746A (ja) 2014-05-01
PT2691413E (pt) 2015-03-25
UY33993A (es) 2012-10-31
HRP20150184T1 (hr) 2015-05-08
CA2830831A1 (en) 2012-10-04
EP2691412A1 (en) 2014-02-05
CN107417766A (zh) 2017-12-01
BR112013024974A2 (pt) 2016-09-06
IL228508A0 (en) 2013-12-31
IL228508B (en) 2018-01-31
MY170637A (en) 2019-08-21
US9090657B2 (en) 2015-07-28
US20140038885A1 (en) 2014-02-06
PH12013502000A1 (en) 2013-12-02
HK1189236A1 (en) 2014-05-30
WO2012131377A1 (en) 2012-10-04
SG193568A1 (en) 2013-11-29
TWI525098B (zh) 2016-03-11

Similar Documents

Publication Publication Date Title
KR101868084B1 (ko) 대환식 화합물 및 그의 제조방법
CN107090476B (zh) Sanglifehrin衍生物及其制备方法
WO2011098805A1 (en) Sanglifehrin based compounds
AU2011346823B8 (en) Sanglifehrin derivatives and methods for their production
Class et al. Patent application title: Macrocyclic Compounds and Methods for Their Production Inventors: Steven James Moss (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Barrie Wilkinson (Cambridge, GB) Assignees: NeuroVive Pharmaceutical AB
HK1189236B (en) Macrocyclic compound and methods for its production

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220609

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220609